Compare SCSC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCSC | ANL |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 869.5M | 998.8M |
| IPO Year | 1997 | 2022 |
| Metric | SCSC | ANL |
|---|---|---|
| Price | $44.18 | $10.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $64.50 | $29.50 |
| AVG Volume (30 Days) | ★ 316.4K | 280.6K |
| Earning Date | 11-05-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.33 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $3,846,260,000.00 | N/A |
| Revenue This Year | $12.92 | $243.83 |
| Revenue Next Year | $5.96 | N/A |
| P/E Ratio | $106.36 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $33.76 | $0.88 |
| 52 Week High | $66.78 | $17.25 |
| Indicator | SCSC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 25.12 | 44.99 |
| Support Level | $34.23 | $8.95 |
| Resistance Level | $46.64 | $11.90 |
| Average True Range (ATR) | 2.78 | 0.95 |
| MACD | -1.57 | 0.22 |
| Stochastic Oscillator | 18.03 | 62.75 |
ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.